Saudi Arabia: Allianz agrees to sell its 51% stake in joint venture

In Jefferies’ recent “Assessing the Wider Implications of a Slimmer Society” report, the firm’s analysts underlined some of the key ways in which Glucagon-like peptide-1 receptor agonists (or GLP-1s) could affect the re/insurance sector.According to the analysts, GLP-1s were originally approved for use in 2005 as a treatment for Type 2 diabetes, and have since proven to help manage the disease as